Overall verdict
Buy
6.6/10
1-year performance
+15.74%
Score breakdown
Up 15.7% over 1 year, 87% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 4.4/10.
22 analysts, target +0.0% vs the price.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.
This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies ;
software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management ; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software.
The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Padraig McDonnell
Founded
1999
Employees
18 100
Revenue / employee
383 867 USD
Next earnings
November 23, 2026
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.72%
- Bank of New York Mellon Corp2.50%
- FMR LLC2.43%
- Rest of the register92.35%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
182.99 USD
52-week low
108.35 USD
1-year performance
15.74%
Rising
Year-to-date performance
27.35%
Rising
Drawdown
-5.19%
Mild pullback
Position in the 52-week range
87% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 2.4 times harder.
$10,000 placed at the end of December 2000 are worth today
| Agilent Technologies | $53,758 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.4 times as much as the world ETF.
- Worst fall:-76Â % between December 2000 and September 2002. $10,000 placed at the top fell to $2,385. The world ETF, at worst: -53Â %. Back to its high in 132 months.
Agilent Technologies earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Agilent Technologies: $53,758
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 119.75 USD - 145.10 USD (comparables only)
The price implies growth of 13.60% per year; the company grows at 14.68%.
Gross margin 53.7%, net margin 19.5%, ROIC 13.9%, ROE 21.0%.
Net margin
19.53%
Exceptional
Sector 3.88%|S&P 13.40%
Gross margin
53.72%
High
Return on equity (ROE)
20.97%
Exceptional
Sector 3.46%|S&P 17.06%
Return on invested capital (ROIC)
13.89%
Exceptional
Free cash flow margin (FCF)
17.19%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.88x
High
Margin stability
4.3 pts
Steady
Revenue to net income
Growth
4.4/10Revenue up 8.1% over 1 year, 5.4% a year over 5, EPS 14.7% a year over 5.
Revenue (trailing 12 months)
7.4Md USD
Revenue growth (1y)
8.06%
Solid
Revenue growth (3y)
1.46%
Moderate
EPS growth (1y)
8.50%
Moderate
EPS CAGR (5y)
14.68%
Strong
EPS revisions (3 months)
2.32%
Revised up
Valuation
5.2/10P/E 34.2x, forward P/E 33.8x, EV/EBITDA 26.6x, PEG 2.33. The multiple sits in the 98th percentile of its own 5-year history.
P/E (TTM)
34.2x
Fair
Sector 50.5x|S&P 23.6x
Forward P/E
33.8x
Fair
EV / EBITDA
26.6x
Fair
Sector 22.4x|S&P 15.5x
PEG
2.33
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
132.43 USD
Overvalued
P/E vs its own 5-year history
among the 2% highest valuations
At its historical high
Market cap
48.9Md USD
Financial strength
4.9/10Cash covers 44.5% of the debt, net debt/EBITDA 0.9x.
Net debt / EBITDA
0.9x
Stretched
Gearing (net debt / equity)
29.76%
Very solid
Cash
1.8Md USD
Cash / market cap
3.59%
Tight
Cash / total debt
44.52%
Solid
Interest coverage
15.5x
Very solid
Net debt
2.2Md USD
Equity
7.4Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 177.88 USD
- MM20175.51
- MM50166.92
- MM200137.36
- RSI 1456.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.67%
200-day average slope, 3 months
+4.80%
50-day average slope, 1 month
+6.84%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.94 % per day
Volatility change
-11.03%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 5.99 (10) | 6.72 (21) | 7 981 (20) | 2 410 (16) | 1 662 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 4, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 52.5Md USD | 39.7x | 41.1 % | -10.2 % | — | -0.2x | — | -24.4 % | ||
| 4 | A | 6.6 | 6.1 | 48.9Md USD | 34.2x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.6 % | 15.7 % | ||
| 5 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 6 | TMO | 6.2 | 5.5 | 266Md USD | 37.9x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 24.6 % | ||
| 7 | LONN | 5.6 | 4.7 | 54.1Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.5 % | 22.7 % | ||
| 8 | MTD | 5.3 | 4.9 | 34.8Md USD | 37.9x | 22.2 % | 6.3 % | 47.4 % | 1.8x | 2.5 % | 21.0 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
